Tempest Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 10, 2023, serves as a current report for Tempest Therapeutics, Inc. (TPST), a Delaware corporation. The filing references the Company's press release announcing financial results for the quarter ended March 31, 2023. The document itself does not contain the detailed financial data but incorporates the press release by reference as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) and are not explicitly stated in the body of this 8-K form.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this filing. The report solely announces the issuance of the Q1 2023 financial results press release.
Guidance, Outlook, and Risks
The filing does not include specific guidance, outlook, management commentary, or risk factors. It notes that the information is furnished under Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 10, 2023) for actual Q1 2023 financial figures.
- Verify the discrepancy in the press release title mentioned in the text ("First Quarter 2022") versus the reported period ("March 31, 2023").
- Confirm the Company's cash position and burn rate from the full press release to assess liquidity runway.
- Check for any updates on clinical trial progress or corporate highlights referenced in the attached exhibit.